Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of sorafenib maintenance
after allo-HSCT in FLT3-negative acute leukemia patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
First People's Hospital of Chenzhou Peking University People's Hospital Second Affiliated Hospital, Sun Yat-Sen University Seventh Affiliated Hospital, Sun Yat-Sen University The First Affiliated Hospital of Guangzhou Medical University The Seventh Affiliated Hospital of Sun Yat-sen University The Third Xiangya Hospital of Central South University Third Affiliated Hospital, Sun Yat-Sen University Xiangya Hospital of Central South University Zhujiang Hospital